Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q4 2020 Earnings Conference Call November 23, 2020 4:30 PM ET Company Participants Jennifer Viera - Senior Director, IR & Corporate Communications Jay Luly - President, CEO & Director Paul Mellett - SVP, Finance & Administration and CFO Conference Call Participants Roy Buchanan - JMP Securities Yasmeen Rahimi - Piper Sandler Eric Joseph - JP Morgan Jay Olson - Oppenheimer Operator Good afternoon and welcome to Enanta Pharmaceuticals fiscal fourth quarter and year-e ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) 2834 (Primary Standard Industrial Classification Code Number) DELAWARE 04-3205099 (S ...

Corporate Presentation August 4, 2020 ENANTA Pharmaceuticals 1 © 2020 | 1 Pl Creating Small Molecule Drugs for Viral Infections and Liver Diseases Forward Looking Statements Disclaimer This presentation contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our research and development programs, our business and the industry in which we operate. Any statements contained herein that are not stateme ...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q3 2020 Earnings Conference Call August 4, 2020 4:30 PM ET Company Participants Jennifer Viera - Senior Director, IR & Corporate Communications Jay Luly - President, CEO & Director Paul Mellett - SVP, Finance & Administration and CFO Conference Call Participants Eric Joseph - JPMorgan Chase & Co. Brian Skorney - Robert W. Baird & Co. Douglas Buchanan - JMP Securities Leonid Timashev - RBC Capital Markets Jay Olson - Oppenheimer Amy Li - Wolfe Research Operator Good ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) 2834 (Primary Standard Industrial Classification Code Number) DELAWARE 04-3205099 ( ...

业绩总结 - EDP-305在12周内的主要终点是至少20%的ALP水平降低或ALP正常化，1mg组和2.5mg组的响应率分别为11%和25%[8] - EDP-305 2.5mg组在ALP水平上显示出显著的改善，P值为0.063，接近统计显著性[9] - EDP-305 1mg组的ALT水平在12周时平均降低了21.51 U/L，P值为0.009，显示出良好的安全性和耐受性[21] - EDP-305 2.5mg组的总胆红素水平在12周时平均降低至8.3 U/L，P值为0.012，表明对肝功能的积极影响[7] - EDP-305 1mg组的GGT水平在12周时平均降低了31.38%，P值小于0.001，显示出显著的疗效[14] - EDP-305 2.5mg组的ALP水平在第8周时平均降低了19.61%，P值为0.039，进一步支持其疗效[10] - 参与者的基线ALP水平在EDP-305 2.5mg组为259.59 U/L，明显低于安慰剂组的320.17 U/L[7] - 研究中，所有参与者均在稳定剂量的UDCA下接受治疗，确保了研究结果的可靠性[6] - 研究显示，EDP-305在改善肝功能方面具有潜在的临床意义，尤其是在ALP和ALT水平的降低上[1] - EDP-305在12周内的安全性和耐受性良好，主要不良事件为轻度至中度，最常见的不良事件包括瘙痒、胃肠道相关症状、头痛和失眠[27] - EDP-305 1mg组和2.5mg组的治疗中断率分别为约3%和18%，而安慰剂组为0%[27] - 在12周时，EDP-305治疗伴随小幅度的绝对脂质变化，显示出对脂质的最小影响[27] - INTREPID研究未达到主要终点，未能在ITT分析中实现ALP至少降低20%的目标，但1mg和2.5mg组的反应率高于安慰剂组[29] - 在完成治疗的患者中，观察到显著的ALP反应[29] - EDP-305 2.5mg组中，普鲁利特发生率为32.1%，而1mg组为35.5%[25] - C4生物标志物在第12周的平均百分比变化为-50%（p=0.042）[28] - EDP-305在超过400名受试者中显示出一致的安全性特征[27] - 研究数据支持在ARGON-2中测试的1.5mg和2mg剂量，以优化靶向作用和安全性/耐受性之间的平衡[29] - EDP-305对甘油三酯和胆固醇的影响较小，显示出良好的耐受性[26]

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q2 2020 Earnings Conference Call May 6, 2020 4:30 PM ET Company Participants Jennifer Viera - Senior Director, IR Jay Luly - President & CEO Paul Mellett - CFO Nathalie Adda - SVP & CMO Conference Call Participants Yasmeen Rahimi - Roth Capital Partners Akash Tewari - Wolfe Research Operator Good afternoon, and welcome to Enanta Pharmaceuticals Fiscal Second Quarter Financial Results Conference Call. [Operator Instructions] There will be a question-and-answer sessi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) 2834 (Primary Standard Industrial Classification Code Number) DELAWARE 04-320509 ...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q1 2020 Results Conference Call February 6, 2020 4:30 PM ET Company Participants Carol Miceli - Director, IR Dr. Jay Luly - President and CEO Paul Mellett - CFO Nathalie Adda - SVP and CMO Conference Call Participants Brian Abrahams - RBC Eric Joseph - JP Morgan Akash Tewari - Wolfe Research Liisa Bayko - JMP Securities Brian Skorney - Baird Iris Long - Berenberg Capital Management Operator Ladies and gentlemen, thank you for standing by, and welcome to the Enanta ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 | --- | --- | --- | |-----------------------------------------|-----------------------------------------------------------------|------------------------------------------ ...